Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Harrow Health Inc
HROW | US
56.42
USD-1.06
-1.84%
HROW | US
About Harrow Health Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
21/10/2024
Close
56.42
Open
57.44
High
57.48
Low
55.87
Harrow Health Inc. an eyecare pharmaceutical company focuses on the discovery development and commercialization of ophthalmic therapies. The company offers ImprimisRx an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe; TRIESENCE a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100 a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals Inc. and changed its name to Harrow Health Inc. in December 2018. Harrow Health Inc. was founded in 1998 and is headquartered in Nashville Tennessee.
View LessHROW | US
Risk
47.0
Sharpe
2.64
Luna's Score
51/100
Recommendation
Hold
Luna says (HROW | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
34.6%1 month
47.0%3 months
119.0%6 months
103.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
34.20
Debt to equity
3.31
Debt to assets
0.63
Ent. to EBITDA
861.59
Ent. to rev.
13.77
PEG
-
Other Fundamentals
EBITDA
3.19M
MarketCap
2.00B
MarketCap(USD)
2.00B
Div. yield
-
Op. margin
3.13
Erngs. growth
-64.00
Rev. growth
46.20
Ret. on equity
-83.70
Short ratio
10.78
Short perc.
16.29
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
10.70
Range1M
16.34
Range3M
37.90
Volumes: Market Activity
Rel. volume
1.40
Price X volume
34.80M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 861.59 | - | Expensive |
| Ent. to Revenue | 13.77 | - | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 34.20 | 13.15 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 119.05 | - | Riskier |
| Debt to Equity | 3.31 | -1.88 | Expensive |
| Debt to Assets | 0.63 | 0.48 | Expensive |
| Market Cap | 2.00B | - | Emerging |
